Novo Nordisk AS (NVO)
102.64
-2.63
(-2.50%)
USD |
NYSE |
Nov 21, 16:00
102.62
-0.02
(-0.02%)
After-Hours: 20:00
Novo Nordisk Revenue (Quarterly): 10.51B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.51B |
| June 30, 2024 | 9.824B |
| March 31, 2024 | 9.519B |
| December 31, 2023 | 9.505B |
| September 30, 2023 | 8.577B |
| June 30, 2023 | 7.936B |
| March 31, 2023 | 7.696B |
| December 31, 2022 | 6.611B |
| September 30, 2022 | 6.169B |
| June 30, 2022 | 5.908B |
| March 31, 2022 | 6.340B |
| December 31, 2021 | 5.896B |
| September 30, 2021 | 5.648B |
| June 30, 2021 | 5.355B |
| March 31, 2021 | 5.480B |
| December 31, 2020 | 5.148B |
| September 30, 2020 | 4.858B |
| June 30, 2020 | 4.431B |
| March 31, 2020 | 5.001B |
| December 31, 2019 | 4.806B |
| September 30, 2019 | 4.510B |
| June 30, 2019 | 4.519B |
| March 31, 2019 | 4.458B |
| December 31, 2018 | 4.545B |
| September 30, 2018 | 4.329B |
| Date | Value |
|---|---|
| June 30, 2018 | 4.391B |
| March 31, 2018 | 4.443B |
| December 31, 2017 | 4.429B |
| September 30, 2017 | 4.206B |
| June 30, 2017 | 4.234B |
| March 31, 2017 | 4.076B |
| December 31, 2016 | 4.288B |
| September 30, 2016 | 4.129B |
| June 30, 2016 | 4.169B |
| March 31, 2016 | 4.023B |
| December 31, 2015 | 4.235B |
| September 30, 2015 | 3.990B |
| June 30, 2015 | 4.007B |
| March 31, 2015 | 3.817B |
| December 31, 2014 | 4.125B |
| September 30, 2014 | 3.956B |
| June 30, 2014 | 3.975B |
| March 31, 2014 | 3.734B |
| December 31, 2013 | 3.959B |
| September 30, 2013 | 3.645B |
| June 30, 2013 | 3.745B |
| March 31, 2013 | 3.536B |
| December 31, 2012 | 3.645B |
| September 30, 2012 | 3.332B |
| June 30, 2012 | 3.362B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.431B
Minimum
Jun 2020
10.51B
Maximum
Sep 2024
6.761B
Average
6.038B
Median
Revenue (Quarterly) Benchmarks
| Ascendis Pharma AS | 63.61M |
| Amgen Inc | 8.503B |
| AstraZeneca PLC | 13.56B |
| Grifols SA | 1.972B |
| Viking Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 4.023B |
| Total Expenses (Quarterly) | 5.525B |
| EPS Diluted (Quarterly) | 0.9019 |
| Enterprise Value | 465.06B |
| Gross Profit Margin (Quarterly) | 84.14% |
| Profit Margin (Quarterly) | 38.28% |
| Earnings Yield | 3.01% |
| Operating Earnings Yield | 3.76% |
| Normalized Earnings Yield | 3.007 |